Purdue Boosts Early-Stage Neuroscience Research With CoCensys Buy
Executive Summary
Purdue Pharma is boosting its early-stage research with the purchase of the neuroscience firm CoCensys for a total cash price of $9.5 mil.
You may also be interested in...
Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Celltech Chiroscience Chirocaine (levobupivacaine) Phase IV commitments include the completion of a cardiovascular resuscitation study in dogs. Chirocaine, which cleared FDA August 5 with an indication for surgical anesthesia and pain management in adults, was deemed "approvable" in February.
Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study
Celltech Chiroscience Chirocaine (levobupivacaine) Phase IV commitments include the completion of a cardiovascular resuscitation study in dogs. Chirocaine, which cleared FDA August 5 with an indication for surgical anesthesia and pain management in adults, was deemed "approvable" in February.
Watson acquires CoCensys sales division, copromotion rights to Somerset Eldepryl, Warner-Lambert Zarontin.
WATSON TO COPROMOTE SOMERSET ELDEPRYL, WARNER-LAMBERT ZARONTIN as part of Watson's agreement to acquire CoCensys' sales and marketing division for $9 mil. in cash. Watson will take over approximately 70 CoCensys U.S. sales personnel through the transaction. CoCensys received $6 mil. on closing, with the balance to be paid upon the occurrence of certain future events.